GleamWall
中文EN

BDPT BIOADAPTIVES, INC.

Pharmaceutical Preparations · OTC · SEC CIK 1575142 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY230.2%
TTM net income YoY-106.3%
TTM EPS YoY—
Revenue 3-yr CAGR0.7%
Net income 3-yr CAGR—

Margins

Gross margin77.0%
Operating margin-3,610.9%
Net margin-8,805.9%
FCF margin—
EBITDA margin-3,587.7%

Returns

ROE—
ROA-2,510.3%
ROIC (approx.)—
Asset turnover0.29x

Leverage & solvency

Liabilities / assets4,703.4%
Debt / equity—
Current ratio0.02x
Interest coverage-2.42x

Cash quality & payout

Operating cash flow / net income0.17x
Accruals ratio-2,071.9%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$4,993$4,988$5,514$10,427$4,632$3,219$0$0
Cost of revenue$979$748$1,401$2,844$781$2,156$0$0
Gross profit$4,014$4,240$4,113$7,583$3,851$1,063$0$0
SG&A expense$235,592$177,745$181,050$228,262$250,971$197,892$143,383$258,621
Operating income-$292,498-$197,176-$198,218-$248,117-$265,689-$279,219-$249,148-$337,339
Interest expense$146,940$115,038$87,757$37,431$14,153$9,649$9,647$9,697
Pretax income-$1.50M$150,090-$111,086-$823,346-$379,502-$157,914-$197,136-$371,788
Net income-$1.50M$150,090-$111,086-$823,346-$379,502-$157,914-$197,136-$371,788
EBITDA-$290,998-$195,676-$196,718-$246,617-$264,189-$278,219-$249,148-$337,339
EPS (basic)-0.010.01——-0.04-0.02——
EPS (diluted)—0.00-0.01—-0.04-0.02-0.02—
Weighted avg. shares (diluted)—281.20M12.01M—10.24M9.53M9.05M—
Balance sheet
Cash & equivalents$5,144$29,221$73,606$158,445$59,273$210,582$39,564$137,470
Short-term investments—$0$0$0———$0
Inventory$34,197$36,046$42,968$44,706$44,228$39,574$40,584$19,115
Current assets$48,006$67,767$123,449$211,901$108,860$255,515$110,448$261,885
PP&E, net$9,500$11,000$12,500$14,000$15,500$17,000—$0
Intangibles———$14,000———$0
Total assets$57,506$78,767$135,949$225,901$124,360$272,515$110,448$261,885
Current liabilities$2.70M$1.84M$2.27M$2.36M$1.59M$1.41M$1.68M$1.73M
Total liabilities$2.70M$1.84M$2.27M$2.36M$1.59M$1.41M$1.68M$1.73M
Shareholders' equity-$2.65M-$1.77M-$2.14M-$2.13M-$1.47M-$1.23M-$1.57M-$1.46M
Shares outstanding223.68M36.60M12.01M12.01M10.94M9.95M9.05M8.22M
Cash flow statement
Operating cash flow-$113,531-$44,385-$84,839-$155,828-$151,309-$110,982-$97,906-$100,538
Capital expenditure$0——$0$0——$0
Free cash flow-$113,531——-$155,828-$151,309——-$100,538
Investing cash flow$0——$0$0——$0
Financing cash flow$89,454——$255,000$0——$194,115
Depreciation & amortization$1,500$1,500$1,500$1,500$1,500$1,000$0$0
Stock-based compensation$388,500——-$310,000$105,000$28,670——

Free plan shows the latest 8 periods; Pro shows all 48 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.